-- 諾華製藥（NVS）週四宣布，已在德克薩斯州丹頓市啟動一座新的放射性配體療法生產設施的建設，這是該公司230億美元美國投資計畫的一部分。 該公司表示，這座位於德州的設施將成為其在美國的第五個放射性配體療法生產基地，預計2028年投產，用於生產個人化癌症療法。 該公司稱，該項目是其未來五年擴大美國生產和研發業務計畫的一部分。
Price: $145.47, Change: $-2.89, Percent Change: -1.95%
Related Articles
Mining & Metals
Earnings Flash (JWEL.TO) Jamieson Wellness Posts Q1 Adjusted EPS C$0.17 per Share; Diluted EPS $0.21
$JWEL.TO
Research
Research Alert: CFRA Lowers Opinion On Shares Of Papa John's International To Hold From Buy
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $4 to $35, 19x our 2026 EPS estimate (down from 20x), a discount to its 26x five-year average justified by competitive headwinds in the pizza quick service restaurant (QSR) industry. We lower our 2026 EPS estimate to $1.83 from $1.94 and 2027's to $2.35 from $2.37. Following Q1 results that included a disappointing performance in North America comp growth (-6.4%), we are lowering our opinion to Hold from Buy. Our previous thesis rested upon the potential for PZZA to translate improvements in its loyalty program, menu, and sales channels into more sustainable comp growth. However, momentum seen in 1H 2025 has faded. In our view, the company's plan to close 300 North American store locations highlights competitive pressures from pizza QSR peers. As a result, PZZA's margin and free cash flow profile have deteriorated more than we thought. Our new Hold opinion contemplates comp momentum in international markets, which is offsetting North American underperformance.
$PZZA
Australia
Earnings Flash (CRWV) CoreWeave Posts Q1 Per Share Loss $-1.40, vs. FactSet Est of Loss $-1.18
Price: $128.97, Change: $-9.01, Percent Change: -6.53%
$CRWV